Drugs / AB001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07214961 | Nov 2025 → Nov 2027 expected | castration-resistant prostate carcinoma | ARTBIO Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03997734 | Jun → Nov 2019 | chronic pain syndrome | Frontier Biotechnologies Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02436824 | Apr → Jul 2015 | chronic pain syndrome | Frontier Biotechnologies Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-07 | ARTBIO Inc. | Regulatory ARTBIO Implements Voluntary Clinical Hold of ARTISAN Trial for Lead Asset AB001 artbio.com ↗
ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), today announced a voluntary hold in enrollment and dosing in its Phase 1 ARTISAN trial for AB001, following the identification of process-related variability. |
| 2025-09-09 | ARTBIO Inc. | Regulatory ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001 artbio.com ↗
ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of Pb212 alpha radioligand therapies (ARTs), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AB001, and confirmed the study may proceed. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03997734 ↗ |
| Modality | Other / unclassified | “an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA)” NCT07214961 ↗ |
| Route | Topical | “repeated topical administration of AB001 topical patches” NCT02436824 ↗ |